47 results about "Myofibrosis" patented technology

The invention relates to the technical field of medicines, and particularly relates to cryptotanshinone for preventing and treating pulmonary fibrosis and an application thereof. The cryptotanshinone (I) is quinone diterpene extracted from the root part of salviae miltiorrhizae; the modern pharmacological research shows that the cryptotanshinone has a bacteriostatic effect, an anti-inflammatory effect and a hormone-like pharmacologic effect, and is clinically used for treating myocardial fibrosis, lung acute injury and arthritis, can be used for preventing and / or treating a pulmonary fibrosis disease, can also be used for preparing medicines for reducing body weight of a pulmonary fibrosis rat, a lung coefficient and the content of hydroxyproline in tissue and can be used for preparing the medicines for reducing the content of IL-1beta, IL-6 and TNF-alpha in a bronchoalveolar lavage liquid and the medicines of effecting the pathogeny structure of pulmonary fibrosis tissue of the rat. The formula (I) is as shown in the specification.

The invention discloses a Chinese herbal medicine preparation for curing angina pectoris, myocardial infarction and preventing in-stent restenosis, which is developed by a cardiovascular disease curing expert and President Shang Xiaoming through the understanding of the pathogenesis of chest stuffiness based on traditional Chinese medical science and the combination of modern pharmacological knowledge. The Chinese herbal medicine preparation comprises the following active pharmaceutical ingredients: danshen root, astragalus, red peony root, angelica sinensis, rhizomaligusticichuanxiong, peach kernel, safflower, hirudo, earth worm and rhizoma pinelliae. The drug is compatible with the dialectic theory of Chinese traditional medicine, which has multiple effects of activating blood circulation to dissipate blood stasis, improving blood circulation, nourishing pneuma and benefiting marrow, soothing nerves and promoting intelligence, can expand peripheral vascular, and improve microcirculation, and can prolong the aggregation time of fibrinogen remarkably and inhibit myocardial fibrosis effectively. Thereby, the Chinese herbal medicine preparation has the advantages of low price, good efficacy, no poison and side effect, and broad market prospects.

The present invention provides a composition for the inhibition of and promotion of recovery from muscular fatigue or muscular damage and diseases associated therewith, in particular, muscular fatigue or muscular damage caused by exercise stress and diseases associated therewith, and a composition for the prevention or treatment of myofibrosis during the restoration at the damaged part associated with or incidental to surgical injury or surgical procedure, which are characterized by comprising as an active ingredient N-(3,4-dimethoxy-cinnnamoyl)anthranilic acid (generic name: tranilast) or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a method for use thereof.

The invention discloses an application of mesaconine. The application is the application of mesaconine or pharmaceutically acceptable salts, esters or solvates of mesaconine in preparation of drugs orhealth care products for preventing and / or treating myocardial fibrosis. Mesaconine can effectively prevent and / or treat myocardial fibrosis and chronic heart failure or cardiac remodeling caused bymyocardial fibrosis.

The invention relates to a heterocyclic benzene sulfonamide compound with a structure as shown in a formula (I) which is described in the specification and an application of the heterocyclic benzene sulfonamide compound in preparation of a ZAK inhibitor. The heterocyclic benzene sulfonamide compound can be used for effectively and highly selectively inhibiting ZAK protein kinase and further regulating the activation of downstream JNK / SAPK, p38, ERK and other pathways. The compound can be used for preparing medicines for preventing and treating various diseases related to ZAK kinase, such as myocardial hypertrophy, myocardial fibrosis, angina pectoris, coronary heart disease, heart failure, myocardial infarction and inflammation, and has the characteristics of better pharmacokinetics, low toxicity and higher druggability.

The invention belongs to the technical field of biomedical engineering, and particularly relates to an artificial cardiac muscle tissue fibrosis model, and a preparation method, a preparation device and an application thereof. The application provides a first artificial cardiac muscle tissue fibrosis model based on human cardiac muscle cells. On one hand, through a tissue engineering technique, humanized artificial cardiac muscle tissue having human body myocardium structure characteristics is constructed, and after uniform and standardized cryodamage treatment, a fibrosis phenotype which is similar to that after miocardial infarction of a human body and is represented by scarring regions produced due to fiber forming cell activation and extracellular matrix deposition can be generated andmake response to medicines; and on the other hand, due to a mature hiPSC-CM disintegration system and a cardiac muscle tissue construction system, the artificial cardiac muscle tissue fibrosis modelcan be constructed at a low cost in batches, test requirements mainly using 96-hole plate for medicine screening are met, the purpose of high-flux medicine test is achieved, and the dilemma that an existing medicine screening system does not have an artificial cardiac muscle fibrosis model for performing related medicine research and development can be avoided.

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

The invention discloses application of a substance for improving activity and / or expression quantity of liver SIRT5 protein in treatment of acute myocardial infarction. Experiments prove that compared with a C57BL / 6 mouse, the myocardial infarction area and the myocardial fibrosis area of the C57BL / 6 mouse of which a liver specifically overexpresses the SIRT5 protein are remarkably reduced, and the cardiac function is improved to a certain extent. Therefore, the substance for improving the activity and / or expression quantity of the liver SIRT5 protein can reduce the myocardial infarction area, reduce the myocardial fibrosis area and improve the cardiac function, and acute myocardial infarction is further prevented and / or treated. The application of the substance for improving the activity and / or expression quantity of the liver SIRT5 protein in treatment of acute myocardial infarction has an important application value.

The present invention discloses a myocardial infarction treating cell preparation, a preparation method and applications thereof, wherein the main components in the cell preparation are CTs and BMSCs. According to the present invention, with the direct intracardiac injection or the interventional intracardiac injection of the cell preparation, by performing cell preparation transplantation on the ischemic area and ischemic margin area of the heart of acute myocardial infarction, the severely damaged cell network formed from CTs in the ischemic myocardium ischemic area can be effectively repaired and regenerated so as to repair the cell structure microenvironment beneficial for the regeneration of the infarcted myocardium, such that the regeneration of the infarcted myocardium is easily achieved; and after the transplantation treatment on the acute myocardial infarction, the effects in the fields of infarction area reducing, myocardial infarction heart cardiac function improving, ischemic myocardium fibrosis improving, ischemic area angiogenesis and marginal area angiogenesis promotion, infarcted heart pathological reconstruction improving and after-myocardial-infarction heart failure incidence reducing are superior to the effect of the current commonly-used separate BMSCs treatment.

The present invention relates to a medical use of Cellular Repressor of E1A-stimulated Genes (CREG), in particular to a use of CREG protein or active fragment thereof in manufacture of a medicament for preventing and / or treating myocardial infarction, a use in manufacture of a medicament for preventing and / or treating ventricular remodeling after myocardial infarction and heart failure after myocardial infarction, a use in manufacture of a medicament for prevention and / or treatment of myocardial ischemia-reperfusion injury, a use in manufacture of a medicament for prevention and / or treatment of salt-sensitive hypertensive myocardial fibrosis.

The invention discloses a nilotinib-loaded heart microneedle patch for targeted myocardial administration and myocardial fibrosis treatment, and a preparation method of the nilotinib-loaded heart microneedle patch. According to the method, GelMA hydrogel with natural biocompatibility and biodegradability is used for loading an anti-fibrosis drug nilotinib; a drug-loaded microneedle patch is prepared through ultraviolet light cross-linking curing; the microneedle patch naturally forms a radian attached to the surface of the heart in the curing process, has good mechanical properties and drug release performance, is attached to the surface of an epicardium, not only can release drugs in a targeted myocardial manner and exert the drug effect at a safe dosage, but also can provide mechanical support for the heart, prevent cardiac rupture, prevent left ventricular remodeling after myocardial infarction, and improve cardiac functions; and the drug-loaded heart microneedle patch has pharmacological and mechanical treatment effects at the same time, has good prospects for treating excessive cardiac fibrosis after myocardial infarction, preventing ventricular remodeling and improving cardiac functions, and has the advantages of high targeting property and high safety.

The invention relates to a pharmaceutical composition for inhibiting myocardial fibrosis, and belongs to the technical field of biological medicines. As the acatinib has relatively high kinase selectivity and relatively good safety, and in a pathological state, BTK in myocardial fibroblasts can be directly combined and phosphorylated with a TGF-beta receptor I (TbetaRI), so that activation of downstream SMAD classical and MAPK non-classical fibrosis signal channels is promoted. The Acalabrutinib can be used for inhibiting phosphorylation and activation of BTK in a targeted manner and reducing the activation of a fibrosis signal channel in a pathological state, so that the occurrence of cardiomyopathy fibrosis is prevented. Therefore, research shows that the BTK inhibitor Acalabrutinib can inhibit myocardial fibrosis reaction under cardiomyopathy conditions (such as myocardial infarction, hypertension, chronic myocardial ischemia and other pathological conditions), so that the cardiac function is protected, adverse cardiac remodeling is prevented, and the occurrence of heart failure is controlled.

The present inventors have found that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect to improve the function of the heart, prevent cardiomyocyte hypertrophy, prevent myocardial fibrosis and promote angiogenesis in an animal model with dilated cardiomyopathy, the specific HMGB1 fragment peptide also exhibits an effect to improve the function of the heart, preventauxocardia, prevent cardiomyocyte hypertrophy, prevent myocardial fibrosis and promote angiogenesis in an animal model with ischemic cardiomyopathy associated with old myocardial infarction, and thespecific HMGB1 fragment peptide exhibits an effect to prevent cardiomyocyte hypertrophy and prevent myocardial fibrosis in an animal model with hypertensive cardiomyopathy. On the basis of this finding, a pharmaceutical composition for preventing and / or treating cardiomyopathy, old myocardial infarction, and chronic heart failure associated with these diseases is provided, which contains an HMGB1fragment peptide having a specific amino acid sequence.

The invention discloses an application of cycloastragenol in prevention and treatment of myocardial fibrosis. The cycloastragenol is applied to one of the following steps (a1) and (a2): (a1) preparinga product for preventing and / or treating myocardial fibrosis; (a2) preventing and / or treating myocardial fibrosis. The cycloastragenol can effectively inhibit a myocardial collagen volume fraction increase, an expression level increase of myocardial fibrosis marker genes in myocardial tissues, an mRNA expression level increase of ANF genes in myocardial tissues, an expression level increase of related inflammatory cytokine genes and the degree of infiltration of inflammatory cells in the heart of the body due to the myocardial fibrosis, and the symptom of irritating dry cough does not occur in experiments of the cycloastragenol. In summary, the cycloastragenol plays an important role in preventing and treating the myocardial fibrosis, and has a great application prospect in the preventionand treatment of the myocardial fibrosis.

The invention relates to a PK (Pyruvate Kinase) M2 mutant and application thereof to cardiovascular diseases. The nucleotide sequence of the PKM2 mutant is shown as SEQ ID NO. 2. The activity of the PKM2 in cells is recovered by using a specific PKM2 agonist or transfecting and modifying site mutation plasmids into cardiac muscle cells, so that the occurrence of myocardial fibrosis and congestiveheart failure can be effectively inhibited.

The invention relates to the technical field of medical treatment, and in particular, relates to an intelligent myocardial fibrosis analysis method and system. The intelligent myocardial fibrosis analysis system comprises a control terminal, a detection hardware, a data acquisition module, an input module, an analysis module and a memory bank; the control terminal is a main control terminal of the detection hardware and controls the detection hardware to execute and send out a command; the detection hardware is used for detecting the myocardial fibrosis condition of the target heart; the input module is used for inputting target parameters; the data acquisition module is used for acquiring target myocardial detection data detected by the detection hardware; the analysis module is used for analyzing and detecting target myocardial data, generating myocardial data parameters and forming a data summary file; and the memory bank is used for storing healthy myocardial data for a user and is a comparison basis of the comparison module. Aiming at the defects embodied in an existing myocardial fibrosis detection technology, the invention provides the intelligent myocardial fibrosis analysis system, when the system is used, accurate diagnosis reference opinions can be provided for doctors, and the doctors can compare and push the reference opinions with own diagnosis results, so that a more accurate and objective diagnosis result can be made for a patient.

The invention discloses application of CAND1 in preparation of a medicine for inhibiting myocardial cell hypertrophy, heart failure and myocardial fibrosis. The NCBI registration number of mRNA of CAND1 is NM _ 027994.1. The prepared medicine can only contain CAND1 and can also be prepared into a medicine compound which contains an effective dose of CAND1 and a pharmaceutically acceptable carrier,wherein the carrier can be virus, cholesterol, nanoparticles, chitosan, lipidosome and the like; the CAND1 is synthesized and wrapped by the carrier to prepare an injection preparation; and the injection preparation is used for treating myocardial hypertrophy, heart failure and myocardial fibrosis in an intravenous or intramuscular injection manner.

The invention discloses an application of calycosin as a TGFBR1 inhibitor and in preparation of medicine for treating ventricular remodeling and myocardial fibrosis, and relates to the technical field of medicines. Based on the natural and safe characteristics of the calycosin, the calycosin provides possibility for treating diseases caused by TGF-beta pathway disorder, and particularly provides an application of the calycosin in the medicine responding to TGFBR1 related diseases.

The disclosure concerns antibodies that bind fibronectin-EDA. These antibodies are particularly useful for use in treatment, prevention, or prevention of progression of fibrosis, adverse cardiac remodeling and conditions resulting from or relating to myocardial infarction and pressure-overload, such as heart failure, aneurysm formation and remote myocardial fibrosis and for use in improving angiogenesis, preferably after ischemic injury.

The invention discloses miRNA markers related to auxiliary diagnosis of myocardial fibrosis diseases and application of the miRNA markers. Hsa-miR-6802-3p and hsa-miR-1229-3p which are differentially expressed in patients suffering from myocardial fibrosis diseases are screened out by a high-throughput sequencing analysis technology, further cell experiments verify that the miRNA biomarkers hsa-miR-6802-3p and hsa-miR-1229-3p can be used in clinical auxiliary diagnosis of myocardial fibrosis, have important significance in early diagnosis of myocardial fibrosis, provide drug targets for clinical preparation of drugs for myocardial fibrosis, and are helpful for realizing targeted therapy of myocardial fibrosis.

The invention discloses application of doxycycline in preparation of a medicine for treating and / or preventing and / or relieving and / or improving cardiomyopathy. According to the invention, doxycycline is applied to treatment of cardiomyopathy, so that the diastolic function of the heart can be recovered, myocardial cell apoptosis can be reduced, and / or myocardial fibrosis and cardiomyopathy can be relieved, e.g. restricted cardiomyopathy.

The invention discloses an application of songlin in a medicine for resisting doxorubicin cardiotoxicity, and particularly relates to an application of songlin in a medicine for resisting doxorubicin cardiotoxicity, resisting heart failure, increasing cardiac ejection fraction and protecting myocardial mitochondrial functions. According to the application disclosed by the invention, the songorine is applied to the medicine for resisting doxorubicin cardiotoxicity and heart failure, so that the cardiac ejection fraction is effectively increased, the myocardial cell apoptosis is prevented, the myocardial mitochondrial function is protected, the myocardial fibrosis is reduced, the tumor cell proliferation inhibition effect of doxorubicin is not reduced while the myocardial cell activity is increased, and the application treatment effect is remarkable; the traditional Chinese medicine composition has no obvious side effect and has a good medicinal prospect.

The invention provides application of a beta-catenin specific inhibitor in preparation of a medicine for treating heart diseases. The beta-catenin specific inhibitor has the effect of treating the heart diseases such as dilated heart disease and myocardial fibrosis. Great clinical significance is realized on further development of related treatment medicines.

The purpose of the present invention is to provide: a composition for inhibiting myofibrosis, which contains, as an active ingredient, a component that can be safely ingested over a prolonged period of time; and a method for safely inhibiting myofibrosis. The present invention provides a composition for inhibiting myofibrosis, which contains quercetin or a glycoside thereof as an active ingredient.

The present invention aims to provide a composition for inhibiting myofibrosis, which contains, as an active ingredient, a component that is safely ingestible for a long period of time; and a method of safely inhibiting myofibrosis. The present invention provides a composition for inhibiting myofibrosis containing quercetin or a glycoside thereof as an active ingredient.

The invention relates to applications of epicatechin in preparation of drugs for preventing or treating myocardial fibrosis, and belongs to the technical field of crude drugs. In order to provide a novel application of the epicatechin, the applications of the epicatechin in preparation of the drugs for preventing or treating myocardial fibrosis is disclosed. The using amount of the epicatechin is0.001-15 mg / Kg (weight / day). The drugs contain effective amount of epicatechin and pharmaceutically acceptable carriers and / or excipient. Through the verification of mouse experiments, the epicatechincan improve the cardiac functions of mice, protect mouse heart structures and relieve AngII induced myofibroblast transformation and collagen synthesis, so that the epicatechin is shown to have the effects of inhibiting myocardial fibrosis and has great application prospects on preventing and treating the myocardial fibrosis; and based on this, the novel applications of the epicatechin in preparation of the drugs for preventing or treating myocardial fibrosis is firstly provided.

The invention relates to a new application of neuropeptide Y, which is mainly used for preparing the drug for myocardial remodeling after acute myocardial infarction. Verified by acute myocardial infarction model mice, neuropeptide Y can improve cardiac dysfunction, reduce myocardial infarct size, reduce myocardial fibrosis, reduce inflammation, and reduce myocardial cell structure damage, thereby reducing the mortality rate of acute myocardial infarction. Myocardial remodeling plays a protective role in myocardial infarction mice.